Lilly announces proof of concept data for neutralizing antibody LY-CoV555 in the COVID-19 outpatient setting

- Primary endpoint of viral load change from baseline at day 11 was met for one of three doses; consistent effects of viral reduction seen at earlier time points   - Rate of hospitalizations and ER visits was 1.7 percent (5/302) for LY-CoV555 versus 6 percent (9/150) for placebo--a 72 percent risk